Fidelity Investments’s Cellectar Biosciences CLRB Stock Holding History

Fidelity Investments’s Portfolio CLRB Stock Details CLRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$25	Buy	+10	New	+$32	﹤0.01%	5343
2024 Q1	–	Sell	-1	Closed	-$50	–	5404
2023 Q4	$50	Sell	1 -1	-50%	-$74	﹤0.01%	5015
2023 Q3	$127	Hold	2	–	–	﹤0.01%	4828
2023 Q2	$96	Buy	+2	New	+$96	﹤0.01%	4963
2021 Q4	–	Hold	0	–	–	–	4392
2021 Q3	–	Hold	0	–	–	–	4414
2021 Q2	–	Hold	0	–	–	–	4309
2014 Q4	–	Sell	-3	Closed	-$224K	–	2795
2014 Q3	$224K	Buy	+3	New	+$259K	﹤0.01%	2733

Other funds holding CLRB

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RCA

Riverview Capital Advisers Boston, Massachusetts $300M AUM 10.98% 1-Year Est. Return

SFA

Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Fidelity Investments's CLRB Position: Q1 2026 in Review

Fidelity Investments opened a new position in Cellectar Biosciences (CLRB) in Q1 2026: 10 shares worth $25. The stake represents ﹤0.01% of the portfolio and ranks #5343 among its holdings. This is a return to the name: Fidelity Investments previously reported a position in CLRB as recently as Q4 2023.

Fidelity Investments first reported a position in CLRB in Q3 2014 and has held it in 5 quarters since. The position peaked at $224K in Q3 2014. 19 funds tracked by Wall St. Rank hold CLRB as of Q1 2026.

Fidelity Investments held 10 shares of Cellectar Biosciences worth $25 as of Q1 2026.
Cellectar Biosciences was a new Fidelity Investments position in Q1 2026.
Cellectar Biosciences made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #5343 holding.
Fidelity Investments first reported a position in Cellectar Biosciences in Q3 2014 and has held it in 5 quarters since.
Fidelity Investments's Cellectar Biosciences position peaked at $224K in Q3 2014.
19 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.